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EXPERT OPINION
Abstract: Restless legs syndrome (RLS) is characterized by paraesthesias–dysesthesias and
motor restlessness worsening at rest–in the evening, with at least temporary relief by activity.
Its etiology is unknown, though it could be secondary to various conditions. It is well known,
however, that dopamine plays a crucial role in the pathophysiology of RLS, as dopaminergic
agonists achieve marked improvement. Pramipexole is a nonergoline compound with selectivity
for D3 dopamine receptors. This drug is very effective in the treatment of idiopathic and
secondary RLS and in treatment-resistant patients, as shown by double-blind, placebo-
controlled studies in adults. In children, studies are much more limited, and RLS is often
misdiagnosed as “growing pain” or attention deficit hyperactivity disorder. Pramipexole has
been successful in open studies, eliminating clinical symptoms. This medication has the
advantage of being free of the frequently encountered problems seen with ergot derivatives.
The side-effects are limited, particularly at the dosages usually prescribed for RLS treatment:
They are much lower than in Parkinson’s disease, and inappropriate sleepiness and sleep
attacks, particularly while driving, or compulsive behavior have not been seen. Compared
with the adverse reactions of levodopa, including tolerance, rebound, and augmentation
phenomena in RLS, which led to usage of dopamine agonists as first line of treatment for
RLS, pramipexole has had one of the best profiles. Augmentation can still be noted with the
drug, but after longer usage time compared with many other dopamine agonists. Although
excessive daytime sleepiness has been noted, sleep attacks have not been encountered in RLS
patients treated with pramipexole.
Keywords: pramipexole, restless legs syndrome, polysomnography, adults, children
About pramipexole
Pramipexole, a nonergoline aminobenzothiazole compound, was approved by the
Food and Drug Administration for the treatment of Parkinson’s disease (PD) in 1997
(Montplaisir et al 1994; Lin et al 1998; Hubble 2000). Pramipexole is a full dopamine
agonist with particular selectivity for D2 dopamine receptor family, and has a 5- to
7-fold higher affinity for D3 receptor subtypes than for either D2 or D4 receptors
(Parkinson Study Group 1997; Lin et al 1998; Hubble 2000). It has a moderate opioid
affinity, only minimal alpha2-adrenoceptor activity, but no other beta-adrenergic or
serotonergic activity (Hubble 2000; Saletu et al 2002).
It is rapidly and well absorbed and not influenced by food. The peak levels of the
drug appear in the bloodstream within 2 hours of oral administration with an absolute
bioavailability of more than 90%, indicating its good absorption and little presystemic
metabolism (Lin et al 1998; Hubble 2000). Binding to plasma proteins is low
(Montplaisir et al 2000a).
Its elimination half-life ranges from 8 to 12 hours (Wright et al 1997; Lin et al
1998). Pramipexole is excreted unmetabolized largely through the kidney, with little
or no interaction with other drugs eliminated by hepatic cytochrome P450 enzymes
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or other related metabolic pathways (Hubble 2000;
Montplaisir et al 2000a). It can therefore be safely used in
patients with hepatic failure or in patients using multidrugs.
It is a “category C” drug in pregnancy (Comella 2002).
About restless legs syndrome
Restless legs syndrome (RLS) was first described by Thomas
Willis in the 17th century, and labeled as a psychosomatic
disease, anxietas tibiarum, by Whittmack in the 19th century
(Whittmack et al 1861; Willis 1685). The first report on
RLS as a sensorimotor and sleep disorder, however, was
written by Ekbom in 1945 (Ekbom 1945). RLS is
characterized by leg paraesthesias–dysesthesias and motor
restlessness worsening at rest and in the evening, with at
least temporary relief by activity (Walters 1995). The
diagnosis of RLS is based on clinical criteria established by
the International RLS Study Group (IRLSSG), and has
recently been modified (Walters 1995; Allen et al 2003)
(Table 1). RLS was found to be the fourth leading cause of
insomnia (Coleman 1982) particularly at sleep onset.
The overall prevalence of RLS is approximately 10%
(Rothdach et al 2000) with variation between 6% and 11%,
depending on the general population survey and the
geographic location of the considered country. The
symptoms are often progressive and tend to worsen with
aging (Comella 2002). The mean age of onset of RLS
symptoms was found to be 27 years (Montplaisir et al 1997).
Although most subjects are not diagnosed for many years,
38%–45% of adult RLS subjects have onset of symptoms
before age 20 years (Montplaisir et al 1997; Walters et al
1996; Restless legs syndrome Study Group 2000), with 13%
of patients reporting symptoms before the age of 10
(Montplaisir et al 1997). Familial aggregation of RLS is
known to be more common in early onset of symptoms
(Allen et al 2003).
The recognition of RLS in childhood is complex. In
1832, Duchamp observed some children suffering aches and
pains, termed “growing pains” (Duchamp 1832). Walters
and colleagues (Walters et al 1994; Walters 1995) and
Ekbom (Ekbom 1975), on the other hand, have stated that
some of these children might actually have RLS. RLS in
childhood may therefore be more common than appreciated.
It is now well known that RLS may begin in childhood
(Picchietti et al 1998, 1999; Walters et al 2000). It was
important to have well defined clinical criteria for the
recognition of RLS in childhood. The IRLSSG proposed
such criteria (Walters 1995; Allen et al 2003) (see Table 2),
but a validation on a general population children group is
needed, despite the fact that this is currently the best
document on the matter.
The etiology of RLS remains unknown. It could be
idiopathic, 50%–92% of which has familial occurrence with
autosomal dominant mode of inheritance (Montplaisir et al
1994; Walters 1995; American Sleep Disorders Association
1997; Comella 2002). Three different genetic loci, 12q,
14q13-21, and 9p (RLS-1, RLS-2, and RLS-3), have been
reported with a recessive (RLS-1) and autosomal dominant
(RLS-2, RLS-3) mode of inheritance, respectively
(Desautels et al 2001; Bonati et al 2003; Winkelmann et al
2005). RLS can also be secondary to various conditions,
including central and peripheral nervous system disorders,
metabolic disturbances, pregnancy, anemia, and so forth
(Collado–Seidel et al 1998; Happe and Trenkwalder 2004).
The most important development in the understanding
of the pathophysiology of RLS was achieved by the
demonstration of dopaminergic hypofunction by Akpinar
(1982), who demonstrated the relief of RLS symptoms by
levodopa treatment. The marked improvement achieved with
dopaminergic agonists, exacerbation of RLS symptoms with
dopamine antagonists, and increased frequency of RLS in
patients with PD suggests that dopamine plays a crucial role
in the pathophysiology of RLS (Comella 2002). In addition,
imaging studies using ligands showed that dopaminergic
activity in the central nervous system, particularly in the
striatonigral system, is reduced in patients with RLS
(Turjanski et al 1999; Ruottinen 2000).
Why pramipexole in RLS
The pharmacological treatment of RLS has developed
greatly since Akpinar (1982) reported complete resolution
of RLS symptoms with levodopa. Later studies consistently
showed the beneficial effects of levodopa given with a
peripheral decarboxylase inhibitor in both primary and also
secondary RLS patients (Brodeur et al 1988; Von Scheele
and Kempi 1990; Trenkwalder et al 1995). Levodopa was
the first drug of choice in RLS, as it is usually well tolerated
in most patients (Chesson et al 1999; Hening et al 1999).
On the other hand, some adverse reactions have limited its
use (Guilleminault et al 1993; Collado–Seidel et al 1999;
Hening et al 1999).
Rebound phenomenon, worsening of symptoms at the
end of a dosing period leading to late-night or morning
recurrence of symptoms (Guilleminault et al 1993; Ferini-
Strambi 2002), is seen in approximately 25% of patients onNeuropsychiatric Disease and Treatment 2006:2(4) 395
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levodopa for RLS (Comella 2002). It has been reported that
35% of RLS patients treated with levodopa for long periods
developed morning restlessness, which resolved within 1
week upon discontinuation (Guilleminault et al 1993). This
complication is most commonly seen when the regular-
release formula of levodopa–carbidopa is used (Ferini-
Strambi 2002). This rebound restlessness may be overcome
by an additional levodopa dose during daytime, but may
also decrease the compliance (Guilleminault et al 1993;
Montplaisir et al 1999).
Augmentation is seen in more than 80% of RLS patients
with long-term use of levodopa, leading to apparent
worsening of symptoms (Allen and Earley 1996; Restless
legs syndrome Study Group 2000; Comella 2002; Saletu et
al 2002). In the augmentation phenomenon, symptoms
progressively increased in severity have an earlier onset in
the day involving the other parts of the body beyond the
legs (Restless legs syndrome Study Group 2000; Earley and
Allen 1996). If augmentation is taken to be a decrease in
drug efficacy, as the dosage is increased, greater
augmentation is seen. Augmentation is more common in
severe RLS patients with a higher dose of medication
(Ferini-Strambi 2002).
Another complication of long-term levodopa treatment
is tolerance, the need for larger doses to maintain the original
effect. Allen and Earley (1996) showed that following about
21 months of treatment, 59% of patients with RLS needed
to increase their levodopa dose. However, the increase in
dosage may also be due to the development of augmentation.
Due to the abovementioned complications of levodopa,
dopamine agonists, with prolonged duration of action, have
become the primary treatment for RLS. It has been shown
in many studies that all dopamine receptor agonists licensed
for PD can also be used effectively in the treatment of RLS
(Brodeur et al 1988). Therefore, dopamine agonists are now
being used as the first choice of treatment, especially in
moderate-to-severe RLS, and in the presence of daytime
symptoms or augmentation (Brodeur et al 1988). In
secondary RLS, the underlying condition should first be
addressed, but dopaminergic drugs may also be helpful
(Comella 2002). However, although D2-receptor agonists
of ergot derivatives, such as bromocriptine (Walters et al
1988) and pergolide (Earley and Allen 1997), are shown
to be effective in RLS, some major and frequent side-
effects limit their usefulness. Some degree of
augmentation with these dopaminergic agonists was also
reported between 9% and 18% in different studies
(Montplaisir et al 2000b; Silber et al 2001; Ferini-Strambi
2002). The augmentation with pergolide, for instance,
was shown to affect 15%–25% of patients (Earley and
Allen 1996; Silber et al 1997). Moreover, it has also been
reported that some degree of symptoms persists even after
treatment with these agents.
Pramipexole, being selective for the D3 receptor and
also a nonergot compound, does not have the frequently
encountered problems seen with dopamine agonists of ergot
derivative (see below). An initial pramipexole follow-up
study in 7 RLS patients showed that none had augmentation
after a mean period of 7.8 months (Montplaisir et al 2000b).
Even if these initial long-term results have not be confirmed
in all cases and presence of augmentation has been shown
with all dopamine agonists tried to date on RLS, pramipexole
Table 1 Clinical features of the restless legs syndrome (RLS) in adultsa (Walters 1995; Allen et al 2003)
Diagnostic features
1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs
2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting
3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching
4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or occur only in the evening or night
Supportive clinical features
1. Positive family history
2. Positive response to dopaminergic therapy
3. Presence of periodic limb movements (during wakefulness or sleep)
Associated features of RLS
1. Variable clinical course, but typically chronic and often progressive
2. Physical examination normal in idiopathic–familial forms
3. Sleep disturbance is a common complaint in more affected patients
aDiagnostic features are those mandatory for a definite clinical diagnosis. Supportive clinical features are those which may increase the probability of a diagnosis in
doubtful cases, such as is common in children. Associated features are typical, but do not contribute to diagnosis.Neuropsychiatric Disease and Treatment 2006:2(4) 396
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has been commonly used without problem for many months.
In addition, pramipexole in the treatment of the symptoms
of RLS has been shown to be very effective.
In rare cases, benzodiazepines, opioids, and
anticonvulsants have also be given, particularly in cases of
treatment failure with dopaminergic agents (Hening et al
1999; Saletu, Anderer, et al 2000; Saletu, Gruber, et al 2000;
Saletu et al 2001). The question of the potential role of IV
infusion of iron as an intermittent treatment or supplemental
treatment of RLS is currently under investigation (Early et
al 2005).
Studies with pramipexole in adult
RLS and periodic limb movements
in sleep (PLMS) patients
Pramipexole in RLS and PLMS
RLS and PLMS
The studies with pramipexole performed in adult patients
have clearly shown that the drug is effective in the treatment
of RLS in placebo-controlled, double-blind studies (Table
3). Compared with levodopa, which improved leg
restlessness by about 40% in a blind-designed study,
pramipexole improved RLS symptoms by about 80%
(Brodeur et al 1988; Happe and Trenkwalder 2004), which
suggests that pramipexole is more potent than levodopa.
However, to compare two different studies with different
diagnostic criteria used in selection of the population
questions this statement, revealing the need for head-to-head
comparative studies. Pramipexole also has a major effect
on PLMS index and PLMS-related arousals when associated
with RLS (Montplaisir et al 1999). Pramipexole has also
been compared with another nonergot dopamine agonist,
the drug ropinirole, which has demonstrated a similar
positive effect on PLMS index. Ropinirole, with a shorter
half-life, has been reported to improve sleep efficiency less
(Saletu, Gruber, et al 2000; Saletu et al 2002). The efficacy
of pramipexole on secondary RLS has also been reported
in many studies, including uremic RLS in dialysis patients
(Miranda et al 2004) (Table 3). All dopaminergic agents,
including pramipexole, are effective in secondary forms of
RLS–PLMS (Boivin et al 1993; Trenkwalder et al 1995;
Manconi et al 2003; Miranda et al 2004). The drug can thus
be used to treat RLS and PLMS associated with underlying
conditions.
Based on both short- and long-term observational and
controlled studies, some also with polysomnography, the
recommended dosage of pramipexole ranges normally
between 0.375 and 0.75 mg/day (Montplaisir et al 1999). A
very low initial optimal therapeutic dose of pramipexole
(0.25 mg/day) was reported to have a very rapid efficacy in
66% of RLS patients (Comella 2002). About 50% of the
studied patients were reported to have moderate or marked
improvement after the first to third administration of such
dosage. This rapid action of pramipexole even at low
dosages is hypothesized to indicate a more specific role of
D3 receptors of the mesolimbic system in the
pathophysiology of RLS (Trenkwalder et al 1996; Comella
2002).
Table 2 Diagnostic criteria for childhood restless legs syndrome(RLS) (Walters 1995; Allen et al 2003)
Definite childhood RLS
1. The child meets all 4 essential adult criteria for RLS (see Table1), and
2. The child relates a description in his or her own words that is consistent with leg discomfort
or
1. The child meets all 4 essential adult criteria for RLS (see Table 1), and
2. Two of 3 following supportive criteria are present:
(a) Sleep disturbance for age
(b) A biological parent or sibling has definite RLS
(c) The child has a polysomnographically documented periodic limb movement index of 5 or more per hour of sleep.
Probable childhood RLS
1. The child meets all essential adult criteria for RLS, except criterion #4 (the urge to move or sensations are worse in the evening or at night
than during the day), and
2. The child has a biological parent or sibling with definite RLS
or
1. The child is observed to have behavior manifestations of lower extremity discomfort when sitting or lying, accompanied by motor movement
of the affected limbs, the discomfort has characteristics of adult criteria 2, 3, and 4 (ie, is worse during rest and inactivity,
relieved by movement, and worse during the evening and at night), and
2. The child has a biological parent or sibling with definite RLS.Neuropsychiatric Disease and Treatment 2006:2(4) 397
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Sleep
Most of the sleep laboratory studies showed that there is no
effect of pramipexole on total sleep time, number of
awakenings, sleep continuity, or sleep efficiency
(Montplaisir et al 1999; Miranda et al 2004). Similar results
were also reported in levodopa trials in RLS patients
(Brodeur et al 1988; Kaplan et al 1993; Trenkwalder et al
1995). It has been found, however, that pramipexole may
delay REM sleep latency and decrease total percentage of
REM sleep (Montplaisir et al 1999). Acute administration
of pramipexole, 0.25mg, has been shown to increase sleep
stages NREM-1 and 2 and stage shifts, while slow-wave
and REM sleep decreased significantly compared with
placebo (Saletu et al 2002). The dopamine agonist pergolide
has also been reported to significantly improve total sleep
time (TST), total sleep period, and sleep efficiency, and also
increase the number of spontaneous awakenings in stage 2
nonREM sleep, and decrease stages 3+4 with the alteration
in the distribution of non REM sleep towards more light
sleep (Wetter et al 1999; Saletu, Gruber, et al 2000) but
with an improvement of subjective sleep quality. Moreover,
a partial antidepressive effect of pramipexole has also been
found, supporting a dopaminergic dysfunction in the
pathogenesis of these two disorders (Saletu et al 2002).
Studies with pramipexole in
childhood RLS and PLMS
There are few studies on RLS in children, and fewer with
pramipexole. But it is now known that RLS is much more
common in children than previously assumed.
Clinical presentations in children
Growing pains
The most common misdiagnosis of childhood RLS is
growing pains (Walters et al 1994). A study of 112 children
diagnosed as having growing pains showed that some
children had sensation of cramps or creeping very similar
to RLS (Walters 2002). A polysomnographic (PSG) study
in 10 children with growing pains showed they all met
clinical criteria for definite RLS (Rajaram et al 2004).
Interestingly, the positive family history of growing pains
was also more common in these children (51.0% vs 12.5%
of children without growing pains) (Walters 2002). In
addition, 7 of 60 patients with age of onset of RLS symptoms
before 20 years reported that they had the diagnosis of
growing pains (Montplaisir et al 1997).
Attention deficit hyperactivity disorder (ADHD)
High prevalence of RLS symptoms in children with ADHD
and PLMS has also been reported (Picchietti et al 1998).
Many children with ADHD have RLS symptoms (eg, leg
paraesthesias) due to their ADHD symptoms (Walters et al
1994). On the other hand, some children with ADHD signs
and symptoms might actually have RLS (Picchietti and
Walters 1994). In addition, many of the parents of children
with ADHD and RLS–PLMS were also shown to have RLS
symptoms or PLMS in some studies (Picchietti and Walters
1994).
To explain the close relationship between ADHD and
RLS–PLMS, a genetic linkage between these two disorders
has been hypothesized, with the possibility that they might
share a common deficit in dopaminergic pathways (Picchietti
et al 1999). This hypothesis is supported by well-known
therapeutic response of RLS–PLMS to dopaminergic agents
(Lin et al 1998; Ondo 1999), as well as the evidence that
ADHD, in some cases, is genetically linked to the
dopaminergic system (La Hoste et al 1996; Waldman et al
1998).
Iron deficiency, low serum ferritin levels (Kryger et al
2002; Kotagal and Silber 2004), diabetes mellitus type 1
(Happe et al 2005), and RLS-like symptoms possibly
associated with streptococcal or Mycoplasma pneumoniae
infections (Matsuo et al 2004) have also been reported as
etiological factors in children with secondary RLS.
Treatment studies
Treatment of childhood RLS remains largely unexplored.
There are some reports on children with ADHD and RLS–
PLMS treated with carbidopa–levodopa and clonidine with
moderate benefit (Walters et al 1994; Rajaram et al 2004),
and clonazepam with no benefit (Picchietti and Walters
1994; Walters et al 1994). Another study was performed on
7 children with RLS–PLMS treated with prescription
dopaminergic drugs, either levodopa or pergolide. The
children had shown no benefit from prior stimulant therapy,
but demonstrated long-term improvement in RLS, PLMS,
and the associated arousals, along with objective and
subjective improvements in ADHD (American Sleep
Disorders Association 1997). However, the effect of
improvement in ADHD symptoms on the amelioration of
RLS–PLMS cannot be excluded. Finally, a study of PLMS
performed in children indicated association of the
polysomnographic findings of PLM with many etiologies,
including association with RLS and with ADHD (Martinez
and Guilleminault 2004)Neuropsychiatric Disease and Treatment 2006:2(4) 398
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There are only 2 studies with pramipexole usage in
childhood RLS–PLMS, both of which were performed at
the Stanford sleep center. The first was carried out in
prepubertal children with sleep disorders. Six children with
PLMS and 2 with RLS and PLMS were given pramipexole,
and 5 out of these 6 had a complete disappearance of their
PLMS demonstrated by follow-up polysomnography and
were able to well tolerate the drug (Martinez and
Guilleminault 2004). These 5 children have been followed
now for a minimum of 3 years. One of the 2 children with
PLM and RLS has developed augmentation after close to 3
years of pramipexole intake. Another had drug intake
terminated by family concerned about long-term intake of
a dopamine agonist, and 3 children are still taking the
dopaminergic agent without side-effects. The 6th child
developed side-effect very soon after initiation of treatment
and was switched to levodopa, and after 2 years to ropinirole.
Parents stopped usage of any drugs after 6 years of treatment
again because of concern about the effect of long-term drug
intake. The other study, of 84 children (5 with sleep terrors
and 79 with both sleep terrors and sleepwalking) with a
control group of 36 healthy children, revealed that 2
sleepwalkers had accompanying RLS. These 2 children had
disrupted sleep during the first sleep cycle. The nocturnal
sleep disruption associated with the RLS–PLM was
hypothesized to possibly be a factor in the occurrence of
sleepwalking events. Each child was treated for RLS with
pramipexole. Follow-up recording showed absence of
PLMS and no report of symptoms of RLS. There was
simultaneous observation of complete absence of
confusional arousals at long-term follow-up with no
parasomnia reported since treatment (Guilleminault et al
2003). These 2 children have been followed for either 2 or
3 years. RLS symptoms and parasomnia have not been
reported at recent follow-up but increase in drug intake has
been necessary in both cases due to reports of reappearance
of mild symptoms of RLS 7 and 9 months ago, respectively.
All children studied (n=7) were all started with the
recommended lowest effective daily dosage, ie, 0.25mg. The
first week, each child was started with 0.125mg taken at
evening meal. When absence of any side-effect at the end
of the first week was observed, each child’s daily dosage
was increased to 0.25mg. The rationale to select the same
dosage as in adults was that dopamine agonists have been
used in children with abnormal movements at higher dosage;
and child metabolism, overall, is faster than adult
metabolism. The current maximum daily dosage
administered to a child is 0.50mg at evening meal.
Observation of side-effects led to immediate interruption
of drug administration, and all children had a general
pediatric examination every 6 months and a simple blood
test evaluation every year.
Side-effects of pramipexole in
patients with RLS
Augmentation–rebound phenomena
As mentioned, augmentation and rebound phenomena are
the main problems that limit the usefulness of levodopa. It
was in the first trials on pramipexole that augmentation or
rebound were reported to be absent with the continunation
of benefits of pramipexole therapy (Montplaisir et al 2000b).
Montplaisir (2000b) had followed 7 RLS patients taking
pramipexole with a mean daily dose 0.125mg for a mean of
7.8 months without augmentation. On the other hand,
subsequent studies have shown that augmentation with
pramipexole, although rare, could be seen. Ferini-Strambi
et al (2002) found that only 9 of 102 RLS patients (9%) had
augmentation after at least 6 months of pramipexole
treatment. Silber et al (2001) reported augmentation with
pramipexole occurring in 18% of 50 RLS patients who had
failed previous dopaminergic treatment. However, nearly
two-thirds of those patients had developed augmentation
with either levodopa or pergolide. An observational study
reported augmentation in 8.5% of patients during long-term
treatment with pramipexole (Ferini-Strambi et al 2001), very
close to the percentage (8.3%) found in another study
(Ferini-Strambi 2002). However, a very high rate of subjects
developing augmentation, 32%, was reported in another
study (Winkelman and Johnston 2004), similar to the ratio
reported for augmentation seen with pergolide (Silber et al
2003), but still lower than the 50% reported in patients
treated with levodopa (Earley and Allen 1996). The authors
who reported the need to increase the initial therapeutic dose
of pramipexole in 32% of their cases mentioned that the
increase could also be due to some degree of tolerance to
the drug or increasing severity of RLS, in addition to RLS
augmentation (Silber et al 2003). Factors such as natural
progression of RLS, fluctuations in underlying disease
severity, or different study designs in terms of inclusion
criteria for patients might be responsible for the discrepancy
noted in the different reports (Winkelman and Johnston
2004). But in this specific study (Winkelman and Johnston
2004) anatomical extension of symptoms was found in only
5% (3/59) of patients, and this percentage involved only
patients who presented augmentation or tolerance.Neuropsychiatric Disease and Treatment 2006:2(4) 401
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The investigations on the possible risk factors associated
with the appearance of augmentation revealed that it was
not related to medication dosage or severity of RLS before
the onset of pramipexole treatment (Ferini-Strambi 2002).
Two factors most likely to affect augmentation were reported
as: (a) pretreatment with levodopa, and (b) secondary RLS
compared with idiopathic RLS (Ferini-Strambi 2002;
Winkelman and Johnston 2004). Patients with a positive
family history and normal electromyographic examination
results were also reported as predictors for augmentation
(Ondo et al 2004).
The risk of observing augmentation was found to be
highest soon after starting treatment, mostly within the first
4 months of treatment (Ferini-Strambi 2002). The shortest
time to augmentation was reported to be 2 months after
initiation of treatment (Silber et al 2003). In the first year of
treatment, about 20% of patients experienced augmentation,
and in the second year, 10% of patients. After 2.5 years, it
has been said that no previously unaffected patient
developed augmentation (Silber et al 2003).
A comparison of carbidopa–levodopa or pergolide
augmentation with pramipexole augmentation revealed that
it was significantly less common with pramipexole (Silber
et al 2003). It is reasonable that augmentation would be
less frequent and less severe with pramipexole than with
levodopa. For a similar reason, morning rebound and
nocturnal penetrations of RLS symptoms were rare. In
general, augmentation with pramipexole appears to be less
severe, and is easily managed by earlier medication dosing
(Silber et al 2003; Winkelman and Johnston 2004).
Sleep attacks
The excessive daytime somnolence in the form of sudden
sleep attacks that are involved even in motor vehicle
accidents was first reported by Frucht et al (1999), with the
use of pramipexole and ropinirole in patients with PD. Since
then, there have been reports of sudden, irresistible sleep
episodes as an adverse effect with dopaminergic agents
(Becker et al 1999) in PD patients. However, this adverse
effect was not encountered in RLS patients treated with
pramipexole (Ferreira et al 2000; Stiasny et al 2000).
Becker et al (1998, 1999) reported daytime somnolence
in 4 out of 16 patients taking pramipexole for RLS. In
another study, excessive daytime sleepiness was noted in
5% of patients (Silber et al 2003). None of these patients
had sleep attacks. However, in this study, 3 patients with
excessive daytime sleepiness with no sleep attacks felt the
need to discontinue the medication (Silber et al 2003).
Stiasny et al (2001) also found that 1 of 24 patients described
sleepiness with no sleep attacks. The lower risk of sleepiness
with pramipexole, especially while driving, could be related
to the differences in dose and timing of medication compared
with PD patients (Parkinson Study Group 2000; Silber et al
2003). This opinion has been emphasized in one study by
comparing doses, as RLS patients are mostly treated with a
mean dose of 0.37 mg/day (Stiasny et al 2000), while PD
patients with sleep attacks had been given pramipexole at a
mean dose of 2.9 mg/day (Ferreira et al 2000).
Other side-effects
The other more common but less serious side-effects of
pramipexole noted in the drug trials for RLS relief include
nausea or dyspepsia, constipation, anorexia, insomnia–
alertness, sleepiness or stiffness during the day, fatigue,
headache, dizziness, fluid retention–edema, and tachycardia
(Weimerskirch and Ernst 2001; Comella 2002; Saletu et al
2002; Hening et al 2004). But these side-effects are reported
as usually affecting a low number of subjects and usually
not causing the drug trial to be interrupted. Although about
40% of patients were reported to have side-effects with the
medication (Silber et al 2003) (Table 4), they occurred at
initiation, and were only mild, tolerable, and transient,
disappearing within 1 week (Montplaisir et al 1999;
Weimerskirch and Ernst 2001; Silber et al 2003). In addition,
one must emphasize that studies that are not placebo-
controlled might overestimate the adverse reactions.
Pramipexole is believed to have fewer adverse effects than
pergolide. Side-effects were reported in 60%–68% of
patients taking pergolide for RLS (Silber et al 1997, 2001;
Stiasny et al 2001).
Table 4 Side-effects in rest legs syndrome (RLS) patients
treated by pramipexole (Silber et al 2003)
Side-effect Number of
patients
affected (%)
Insomnia 8 (13)
Nausea or dyspepsia 7 (12)
Postural lightheadedness 6 (10)
Excessive daytime sleepiness 3 (5)
Nasal stuffiness 3 (5)
Limb numbness or pain 2 (3)
Headache 1 (2)
Anxiety 1 (2)
Depression 1 (2)
Peripheral edema 1 (2)
Constipation 1 (2)
Palpitations 1 (2)Neuropsychiatric Disease and Treatment 2006:2(4) 402
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It must be emphasized that Martinez and Guilleminault
(2004) report a child treated for PLMS with pramipexole
who had treatment terminated soon after beginning of drug
intake due to increased daytime sleepiness and behavior
changes that included “blunted affect” and personality
change with “strangeness” as verbalized by parents. These
effects were seen at 0.25 mg/day. Interruption of treatment
led to return to normal behavior within 3 days.
Overall potential side-effects of
pramipexole
Side-effects of pramipexole have been well published
previously for its usage in PD, a pathology not considered
here. Patients with either early or advanced PD were enrolled
in clinical trials. Patients with early disease had no
concomitant levodopa therapy, while patients with advanced
PD received a combined treatment of levodopa along with
pramipexole.
In double-blind, placebo-controlled trials of patients with
early PD, the most commonly observed adverse events were
reported as nausea, dizziness, somnolence, constipation,
asthenia, and hallucinations (Parkinson Study Group 1997;
Pogarell et al 2002; Wong et al 2003) (Table 5).
Approximately 12% of 388 patients with early PD
discontinued treatment due to adverse events, compared with
11% of 235 patients taking placebo. The most common
adverse events associated with discontinuation were found
to be hallucinations, dizziness, somnolence, extrapyramidal
syndrome, headache, confusion, and nausea. It must be
remembered that not only the dosage but also the
Table 5 Treatment-emergent adverse events in early
Parkinson’s disease (combined data from: Parkinson Study
Group [1997]; Pogarell et al [2002]; Wong et al [2003])
Adverse events Pramipexole Placebo
(n=388) (n=235)
Asthenia 14 12
General edema  5 3
Malaise 2 1
Reaction unevaluable 2 1
Fever 1 0
Nausea 28 18
Constipation 14 6
Anorexia 4 2
Dysphagia 2 0
Peripheral edema  5 4
Decreased weight 2 0
Dizziness 25 24
Somnolence 22 9
Insomnia 17 12
Hallucinations 9 3
Confusion 4 1
Amnesia 4 2
Hypesthesia 3 1
Dystonia 2 1
Akathisia 2 0
Thinking abnormalities 2 0
Decreased libido 1 0
Myoclonus 1 0
Vision abnormalities  3 0
Impotence 2 1
Table 6 Treatment-emergent adverse events in Advanced
Parkinson’s Disease (Lieberman et al 1997; Kunig et al 1999;
Pinter et al 1999).
Adverse events Pramipexole Placebo
(n=260) (n=264)
Accidental injury  17 15
Asthenia 10 8
General edema  4 3
Chest pain  3 2
Malaise 3 2
Postural hypotension 53 48
Constipation 10 9
Dry-mouth 7 3
Peripheral edema 2 1
Increased creatinin PK 1 0
Arthritis 3 1
Twitching 2 0
Bursitis 2 0
Myasthenia 1 0
Dyskinesia 47 31
Extrapyramidal syndrome 28 26
Insomnia 27 22
Dizziness 26 25
Hallucinations 17 4
Dream abnormalities 11 10
Confusion 10 7
Somnolence 9 6
Dystonia 8 7
Gait abnormalities 7 5
Hypertonia 7 6
Amnesia 6 4
Akathisia 3 2
Thinking abnormalities  3 2
Paranoid reaction 2 0
Delusions 1 0
Sleep disorders 1 0
Dyspnea 4 3
Rhinitis 3 1
Pneumonia 2 0
Skin disorders 2 1
Accommodation abnormalities 4 2
Vision abnormalities  3 1
Diplopia 1 0
Urinary frequency 6 3
Urinary tract infection 4 3
Urinary incontinence 2 1Neuropsychiatric Disease and Treatment 2006:2(4) 403
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neurological lesions are very different between RLS and
PD.
An interesting side-effect of pramipexole, pathological
gambling in PD patients, was recently reported in 2 studies
(Driver-Dunckley et al 2003; Dodd et al 2005). Out of a
total of 1884 PD patients, 529 were treated with
pramipexole, 421 with ropinirole, and 331 with pergolide
(Driver-Dunckley et al 2003). Seven men and 2 women were
found to have symptoms of obsessive or excessive gambling.
Of these 9 subjects, 8 were on pramipexole (mean dosage
4.3 mg/day, range 2–8 mg/day) and 1 was on pergolide
(4.5 mg/day) at the onset of symptoms. In the second paper
(Dodd et al 2005), pramipexole was the agonist in 9 of 11
PD patients who developed pathological gambling within 3
months of treatment or more, with demonstrated resolving
of the gambling problem after discontinuation of the drug.
A survey very recently performed on 32 of our RLS patients
who took pramipexole on a daily basis for over a year did
not elicit any indication of obsessive behavior change since
the start of medication, but considering the very large
number of patients with PD necessary to demonstrate
presence of this side-effect, our sample is most likely too
small.
In double-blind, placebo-controlled trials with
pramipexole and concomitant levodopa in patients with
advanced PD, the most common adverse events were
orthostatic hypotension, dyskinesia, extrapyramidal
syndrome, insomnia, dizziness, hallucinations, accidental
injury, dream abnormalities, confusion, constipation,
asthenia, somnolence, dystonia, gait abnormality,
hypertonia, dry mouth, amnesia, and urinary frequency
(Lieberman et al 1997; Kunig et al 1999; Pinter et al 1999)
(Table 6). Approximately 12% of 260 patients discontinued
treatment due to adverse events compared with 16% of 264
patients receiving placebo. The events most commonly
causing discontinuation were noted as hallucinations,
dyskinesia, extrapyramidal syndrome, dizziness, and
confusion orthostatic hypotension.
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